tbuckley/cabot-search huggingface dataset:
An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.
Authors: Assuntina Gesualda Sacco, Ruifeng Chen, Debanjali Ghosh, Deborah J.L. Wong, Francis P. Worden, Douglas Adkins, Emily Pittman, Karen Messer, Kathryn A. Gold, Gregory A. Daniels, Paul Swiecicki, Brian Sutton, Amanda Natsuhara, Ezra E.W. Cohen
Journal: Journal of Clinical Oncology (2019)

6033 Background: Pembrolizumab (a humanized monoclonal antibody blocking programmed death receptor-1[PD-1]), and cetuximab (a chimeric monoclonal antibody inhibiting epidermal growth factor receptor) are both FDA-approved, second-line monotherapies for R/M HNSCC. This is the first trial to evaluate anti-tumor efficacy of dual therapy with pembrolizumab and cetuximab. Previously reported safety data demonstrated favorable toxicity. An interim futility analysis of cohort 1 (anti-PD-1/PD-L1 and cetuximab naïve) was completed per protocol. Methods: Patients (pts) with platinum-refractory/ineligible, R/M HNSCC were treated with pembrolizumab 200mg IV on day 1 and cetuximab 400mg/m2 loading dose followed by 250mg/m2 weekly (21-day cycle). Primary endpoint: overall response rate (complete and partial responses) by 6 months (mo). Secondary endpoints: 12-mo progression-free survival (PFS) probability, overall survival, response duration, safety, correlative analyses. Results: 14 evaluable pts were enrolled March 2017-October 2018. Median age 60y (range 47-86y), M:F 6:8, ECOG (0:1) 2:12, 14 mucosal primaries (9 oral cavity, 2 HPV-mediated oropharynx, 2 non-EBV-associated nasopharynx, 1 larynx). 11 pts (79%) had no prior lines of systemic therapy for R/M HNSCC (range 0-1). 6 pts (42.8%) had a partial response by 6 months, meeting pre-planned criteria for trial continuation. 4 pts (28.6%) had stable disease and 4 (28.6%) had progressive disease. Median PFS was 128 days (4.3 mo). Median duration of response was 160.5 days (5.4 mo) for partial responders and 133 days (4.4 mo) for pts with stable disease. Disease control rate (partial + stable) was 71.4%. There were 7 grade 3 treatment-related toxicities. 2 pts discontinued cetuximab due to toxicity, however, both continued pembrolizumab. Conclusions: Interim analysis indicates that pembrolizumab plus cetuximab is potentially active for platinum-refractory/ineligible pts with R/M HNSCC. These results meet protocol specifications for trial continuation. Final results will include PD-L1 expression data. Clinical trial information: NCT03082534.
Gas Chromatography. Mass Spectrometry Analysis of 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine in Urine and Feces
Authors: Marlin D. Friesen, Liliane Garren, Jean-Claude Bereziat, Fred Kadlubar, Dongxin Lin
Journal: Environmental Health Perspectives (1993)
ENZYMES AND THEIR ACTIVITY
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Notes
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of Folic Acid for Prevention of Spina Bifida and Other Neural Tube Defects—1983-1991
Journal: JAMA (1991)

Neural tube defects--including spina bifida, anencephaly, and encephalocele--are common, serious birth defects that are important causes of infant mortality and disability. Women in the United States who have had a pregnancy resulting in an infant or fetus with a neural tube defect have a 2%-3% risk for having another pregnancy resulting in an infant or fetus with a neural tube defect (i.e., a recurrence) The British Medical Research Council (MRC) Vitamin Study Group recently reported the results of a randomized prevention trial that indicated that daily oral supplementation with folic acid before conception and during early pregnancy substantially reduces the recurrence of neural tube defects. This report summarizes the findings of that study and provides recommendations for supplementation with folic acid to prevent the recurrence of neural tube defects.
ESGE News and Upcoming Events February 2018
Journal: Endoscopy (2018)

With a new congress it is always difficult to gauge how things will go and the extent of the response rate. The scientific committee was extremely happy to learn that over 750 abstract and endoscopic video submissions were received from authors in more than 55 countries! The committee would like to extend its thanks to all the authors who submitted their work. The next challenge was reviewing the submissions, which was no small undertaking. The scientific committee worked extremely hard, within a very short timeframe, to evaluate each and every submitted abstract and video. We are pleased to inform you that all accepted abstracts will appear in Endoscopy.
Good News, Bad News, Good News
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<scp>2021</scp>clinical trials update: Innovations in hemophilia therapy
Authors: Stacy E. Croteau, Michael Wang, Allison P. Wheeler
Journal: American Journal of Hematology (2020)

Therapies engineered to prolong clotting factor protein circulation time, manipulate the balance of pro-coagulant and anti-coagulant proteins, or introduce new genetic material to enable endogenous factor protein production dominate the clinical trial landscape of hemophilia. The availability of clotting factor concentrates and the establishment of primary prophylaxis have dramatically improved health outcomes for hemophilia patients. But, the burden of hemostatic therapy remains significant, and many barriers to consistent longitudinal use of prophylaxis exist. Several types of emerging therapeutics including engineered factor concentrates, substitutive therapies, rebalancing therapies, and gene transfer/editing all aim to reduce the challenges of current hemophilia treatment. Emerging treatment options may reduce treatment frequency or need for intravenous administration. They may also introduce new challenges in laboratory assessment of hemostasis. These novel therapies must not introduce significant new health risks and continue to support similar or improved outcomes. The potential ramifications of rebalancing the coagulation cascade, particularly in a stress or inflammatory state, or introduction of new genetic material are not trivial. The focus of this review is to provide an overview of active and recently completed clinical trials as well as emerging preclinical data investigating new therapeutic possibilities for hemophilia patients and potentially other rare bleeding disorders.
Meaningful Use
Authors: Mark Vierra
Journal: Annals of Internal Medicine (2016)

On Being a Doctor15 November 2016Meaningful UseMark Vierra, MDMark Vierra, MDFrom Monterey County Surgical Associates, Monterey, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-2669 Audio Reading - “Meaningful Use” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Meaningful Use," by M. Vierra. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I have mixed feelings when I see that Bob is on my schedule today. On the one hand, we are fond of each other and I look forward to seeing him in the way that one looks forward to catching up with an old friend. But it is a 3-hour drive, and today it is windy and raining on the Pass. The roads will be dangerous, and he is 82 years old. I think to call him and tell him to postpone his visit, but I realize that he is already most of the way here and am skeptical that ... Author, Article, and Disclosure InformationAffiliations: From Monterey County Surgical Associates, Monterey, California.Corresponding Author: Mark Vierra, MD, Monterey County Surgical Associates, 2 Upper Ragsdale, Suite 230, Building B, Monterey, CA 93940. PreviousarticleNextarticle Advertisement Audio Reading - “Meaningful Use” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Meaningful Use," by M. Vierra. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 November 2016Volume 165, Issue 10Page: 739KeywordsChildrenComputersEmotionsGamesHand strengthHerniaLungsMusclesNursing homesRunning ePublished: 15 November 2016 Issue Published: 15 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Capitation and the Medicaid Elderly
Authors: Nicole Lurie
Journal: Annals of Internal Medicine (1994)

Letters15 September 1994Capitation and the Medicaid ElderlyNicole Lurie, MD, MSPH, Jon Christianson, PhD, and Ira Moscovice, PhDNicole Lurie, MD, MSPHSearch for more papers by this author, Jon Christianson, PhDSearch for more papers by this author, and Ira Moscovice, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-6-199409150-00033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:At this time, the only way capitation can legally be implemented in a dually enrolled Medicare and Medicaid population is to capitate the Medicaid portion. Although this technically represents the copayment, it actually represented about half of patient expenditures for care in Minnesota. This is because Medicaid covers many services that Medicare does not. We believe it is important that in this particular real-world setting, enrolling dually enrolled Medicare/Medicaid beneficiaries in managed care plans was not measurably harmful to their health.Careful monitoring will be necessary to see if our findings are generalizable to settings in which the ... Author, Article, and Disclosure InformationAuthors: Nicole Lurie, MD, MSPH; Jon Christianson, PhD; Ira Moscovice, PhD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 September 1994Volume 121, Issue 6Page: 469-470KeywordsElderlyMedicare ePublished: 15 August 2000 Issue Published: 15 September 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
"THE CLINICAL APPLICATION OF THE AUDION AMPLIFIER"
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systematic Sclerosis
Authors: John T. Ingram
Journal: British Journal of Dermatology (1962)

Journal Article Systematic Sclerosis Get access John T. Ingram John T. Ingram Newcastle upon Tyne Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 74, Issue 11, 1 November 1962, Page 425, https://doi.org/10.1111/j.1365-2133.1962.tb13439.x Published: 01 November 1962
Effects of Toxic Chemicals on the Reproductive System
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population
Authors: P Lange, J Parner, E Prescott, C Suppli Ulrik, J Vestbo
Journal: Thorax (2001)

BACKGROUND Recent evidence suggests a role for hormonal factors in the aetiology of asthma. METHODS Data from a large study of women selected from the general population were used to relate treatment with oral hormonal contraceptives (OCP) and postmenopausal hormone replacement therapy (HRT) to the following asthma indicators: self-reported asthma, wheezing, cough at exertion, and use of medication for asthma. The study sample comprised 1536 premenopausal and 3016 postmenopausal women who participated in the third round of the Copenhagen City Heart Study in 1991–4. A total of 377 women were taking OCP (24.5% of premenopausal women) and 458 were on HRT (15.2% of postmenopausal women). RESULTS In premenopausal women 4.8% reported having asthma. The prevalence of self-reported asthma, wheeze, use of asthma medication, and cough at exertion was not significantly related to use of OCP. In postmenopausal women the prevalence of self-reported asthma was 6.2%. A weak but consistent association was observed between HRT and self-reported asthma (OR 1.42 (95% CI 0.95 to 2.12)), wheeze (OR 1.29 (95% CI 1.02 to 1.64)), cough at exertion (OR 1.34 (95% CI 1.01 to 1.77)), and use of asthma medication (OR 1.45 (95% CI 0.97 to 2.18)). CONCLUSIONS In this study of the general population no relationship was found between the use of OCP and asthma. Although an association was observed between HRT and asthma and asthma-like symptoms, this was relatively weak and it is concluded that there is no necessity to change present prescription practice.
A Century of International Dermatological Congresses: An Illustrated History 1889-1992
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table_of_Contents
Authors: G Oxnard, M Morris, F Hodi, L Baker, M Kris, A Venook, L Schwartz, E Amir, P Bedard, A Ocaña, B Seruga, T Boyle, T Keegel, F Bull, Y Song, J Manson, I-Min Lee, N Cook, L Paul, J Selhub, E Giovannucci, S Zhang, J Nelfinavir, R Shim, K Rao, L Beebe, I Neckers, R Han, J Nahta, S Shiels, R Pfeiffer, A Chaturvedi, A Kreimer, E Engels, C.-P Wen, J Lin, Y Yang, M Tsai, C Tsao, C Etzel, M Huang, C Hsu, Y Ye, L Mishra, E Hawk, X Wu, W Harms, M Response, E Martínez, J Jacobs, J Baron, T Marshall, M Stefanek, V Cancers, R Cogliano, K Baan, Y Grosse, B Lauby-Secretan, F Ghissassi, V Bouvard, L Benbrahim-Tallaa, N Guha, C Freeman, L Galichet, C Wild, Y Bao, D Michaud, D Spiegelman, D Albanes, K Anderson, L Bernstein, P Van Den Brandt, D English, J Freudenheim, C Fuchs, G Giles, R Goldbohm, N Håkansson, P Horn-Ross, E Jacobs, C Kitahara, J Marshall, A Miller, K Robien, T Rohan, A Schatzkin, V Stevens, R Stolzenberg-Solomon, J Virtamo, A Wolk, R Ziegler, S Smith-Warner, Cancer Survival, C Quinten, J Maringwa, C Gotay, F Martinelli, C Coens, B Reeve, H Flechtner, E Greimel, M King, D Osoba, C Cleeland, J Ringash, J Schmucker-, M Koch, J Taphoorn, A Weis, Lung Cancer, D.-T Chen, Y.-L Hsu, W Fulp, D Coppola, E Haura, T Yeatman, W Cress, Resected Cancers, C Hatzis, H Sun, H Yao, R Hubbard, F Meric-Bernstam, G Babiera, Y Wu, L Pusztai, W Symmans, S Azzi, S Bruno, J Giron-Michel
Journal: JNCI Journal of the National Cancer Institute (2012)
PRESIDENT-ELECT DR. JOHN A. WYETH.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Internal Medicine (2014)

Time Trends of Food Intake Between Statin Users and Nonusers 1038Guidelines recommend both dietary control and statin use to treat high blood cholesterol level, but the recent time trend of food intake among statin users is unknown.Sugiyama and coauthors investigated whether the temporal trend of dietary intake differs by statin use among US adults using National Health and Nutrition Examination Survey data from 1999 through 2010.In 1999-2000, caloric intake was 179 kcal/d less for statin users than for nonusers, but by 2009-2010, owing to a 9.6% increase of caloric intake among statin users and a 1.9% decrease among nonusers, caloric intake no longer differed by statin use.Dietary recommendations may need to be reemphasized for statin users.An Editor's Note from Redberg gives clinical context to the findings.